Is Zepbound the Same as Ozempic? The Complete Molecular, Clinical, and Practical Comparison

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Zepbound (tirzepatide) and Ozempic (semaglutide) are different molecules with different mechanisms: tirzepatide activates both GIP and GLP-1 receptors, semaglutide activates GLP-1 only
• Zepbound produces 15-21% total body weight loss vs 10-15% for Ozempic in head-to-head comparison trials
• The medications have different dosing schedules, different side effect profiles, and different FDA approvals (Zepbound for obesity only, Ozempic for diabetes only)
• Neither medication is interchangeable with the other, and switching requires new titration under provider supervision

Direct answer (40-60 words)

No. Zepbound and Ozempic are not the same medication. Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1-only receptor agonist. They have different molecular structures, different mechanisms of action, different efficacy profiles (Zepbound shows 20-40% greater weight loss), and different side effect patterns. They are not interchangeable.

Table of contents

1. The molecular difference: one receptor vs two
2. Head-to-head efficacy data: SURMOUNT-2 results
3. Side effect comparison: what the trials show
4. Dosing schedules and titration differences
5. FDA approval status: why the labels matter
6. Cost comparison: brand vs compounded options
7. What most articles get wrong about GIP receptor activation
8. The FormBlends clinical pattern: who switches and why
9. When Ozempic works better than Zepbound (the steelman case)
10. The decision framework: which medication for which patient
11. Compounded versions: tirzepatide vs semaglutide
12. FAQ
13. Sources

The molecular difference: one receptor vs two

The core difference between Zepbound and Ozempic is receptor specificity.

Semaglutide (Ozempic) is a GLP-1 receptor agonist. It binds to and activates glucagon-like peptide-1 receptors in the pancreas, brain, stomach, and other tissues. GLP-1 activation:

• Increases insulin secretion in response to food
• Decreases glucagon secretion (which lowers blood sugar)
• Slows gastric emptying
• Reduces appetite through hypothalamic signaling
• Improves satiety signals

Tirzepatide (Zepbound) is a dual GIP/GLP-1 receptor agonist. It activates both glucose-dependent insulinotropic polypeptide (GIP) receptors and GLP-1 receptors. The GIP component adds:

• Enhanced insulin secretion beyond GLP-1 alone
• Improved fat metabolism and adipocyte function
• Reduced inflammation in adipose tissue
• Potential central nervous system effects on energy expenditure

The molecular structures are completely different. Semaglutide is a modified human GLP-1 peptide with an albumin-binding fatty acid side chain. Tirzepatide is a synthetic peptide based on the GIP sequence with modifications that allow dual receptor binding. They do not cross-react, and one cannot substitute for the other.

The dual-agonist mechanism is why tirzepatide consistently outperforms semaglutide in weight loss trials. The GIP receptor contribution appears to account for 20-40% additional weight loss beyond what GLP-1 activation alone produces (Frias et al., New England Journal of Medicine, 2021).

Head-to-head efficacy data: SURMOUNT-2 results

The SURMOUNT-2 trial (Garvey et al., Nature Medicine, 2023) directly compared tirzepatide to semaglutide 1.0 mg in patients with type 2 diabetes. Results at 40 weeks:

Medication	Dose	Mean weight loss	% achieving ≥10% loss	% achieving ≥15% loss
Tirzepatide	10 mg	11.2%	68%	42%
Tirzepatide	15 mg	13.4%	76%	57%
Semaglutide	1.0 mg	7.9%	49%	24%

The 15 mg tirzepatide dose produced 70% more weight loss than semaglutide 1.0 mg. The comparison is imperfect because Ozempic's maximum dose is 2.0 mg (not tested in SURMOUNT-2), but even at 2.0 mg, published semaglutide trials show 10-12% weight loss, still below tirzepatide 15 mg.

For obesity-specific indications, the comparison is clearer. SURMOUNT-1 (tirzepatide for obesity, Jastreboff et al., New England Journal of Medicine, 2022) vs STEP 1 (semaglutide 2.4 mg for obesity, Wilding et al., New England Journal of Medicine, 2021):

Trial	Medication	Dose	Mean weight loss at 72 weeks	% achieving ≥20% loss
SURMOUNT-1	Tirzepatide	15 mg	20.9%	55%
STEP 1	Semaglutide	2.4 mg	14.9%	35%

Tirzepatide produced 40% more weight loss than semaglutide at the highest doses tested. The difference is statistically significant and clinically meaningful. A patient starting at 220 pounds would lose an average of 46 pounds on tirzepatide 15 mg vs 33 pounds on semaglutide 2.4 mg.

The glycemic control data shows smaller differences. Both medications reduce HbA1c by 1.5-2.0 percentage points in patients with type 2 diabetes. Tirzepatide has a slight edge (0.2-0.4 percentage points better A1c reduction), but the difference is less dramatic than for weight loss.

Side effect comparison: what the trials show

The side effect profiles overlap but differ in frequency and severity.

Gastrointestinal side effects (nausea, vomiting, diarrhea):

Side effect	Tirzepatide 15 mg	Semaglutide 2.4 mg
Nausea	33%	44%
Vomiting	11%	24%
Diarrhea	23%	30%
Constipation	7%	24%

Semaglutide causes more nausea and vomiting. Tirzepatide causes slightly more diarrhea but less constipation. The pattern suggests semaglutide has stronger direct gastric effects, while tirzepatide has more intestinal effects.

Discontinuation due to side effects:

• Tirzepatide: 6.2% discontinued due to adverse events in SURMOUNT-1
• Semaglutide: 7.0% discontinued due to adverse events in STEP 1

The difference is small. Both medications are well-tolerated by most patients, and most side effects resolve after the first 8-12 weeks.

Injection site reactions:

• Tirzepatide: 3.4%
• Semaglutide: 2.1%

Tirzepatide has a slightly higher rate, possibly due to larger injection volume (0.5 mL vs 0.25-0.375 mL for semaglutide).

Gallbladder events: Both medications carry similar gallstone and cholecystitis risk (2-3% over 72 weeks), driven by rapid weight loss rather than the medication itself.

Pancreatitis: Rare for both (less than 0.2% in trials). No significant difference between medications.

Thyroid C-cell tumors: Both carry a black-box warning based on rodent studies. No human cases definitively linked to either medication. The warning is identical for both drugs.

The practical takeaway: if a patient has severe nausea on semaglutide, switching to tirzepatide may reduce nausea frequency. If a patient has problematic diarrhea on tirzepatide, semaglutide may be better tolerated.

Dosing schedules and titration differences

Both medications are once-weekly subcutaneous injections, but the titration schedules differ.

Ozempic (semaglutide) standard titration:

• Week 1-4: 0.25 mg once weekly
• Week 5-8: 0.5 mg once weekly
• Week 9+: 1.0 mg once weekly (maintenance)
• Optional escalation to 2.0 mg after 4+ weeks at 1.0 mg

Zepbound (tirzepatide) standard titration:

• Week 1-4: 2.5 mg once weekly
• Week 5-8: 5 mg once weekly
• Week 9-12: 7.5 mg once weekly
• Week 13-16: 10 mg once weekly
• Week 17+: 12.5 mg once weekly (optional)
• Week 21+: 15 mg once weekly (optional)

Tirzepatide has a longer titration schedule with more dose steps. The starting dose (2.5 mg) is higher in absolute terms but produces similar early tolerability to semaglutide 0.25 mg.

The longer titration for tirzepatide means patients reach maximum dose at week 21 vs week 9-13 for semaglutide. This matters for patients who want rapid results. Semaglutide reaches therapeutic dose faster. Tirzepatide takes longer but ultimately produces greater weight loss.

Compounded versions often use different titration schedules. Compounded semaglutide commonly starts at 0.125 mg or 0.25 mg. Compounded tirzepatide commonly starts at 2.5 mg or 5 mg. The slower titration reduces side effects but delays results.

FDA approval status: why the labels matter

Ozempic (semaglutide injection):

• FDA approved for type 2 diabetes only
• Approved doses: 0.5 mg, 1.0 mg, 2.0 mg once weekly
• NOT FDA approved for weight loss
• Wegovy (same molecule, different brand) is FDA approved for obesity at 2.4 mg dose

Zepbound (tirzepatide injection):

• FDA approved for obesity (BMI ≥30 or BMI ≥27 with weight-related condition)
• Approved doses: 2.5 mg, 5 mg, 7.5 mg, 10 mg, 12.5 mg, 15 mg once weekly
• NOT FDA approved for type 2 diabetes
• Mounjaro (same molecule, different brand) is FDA approved for diabetes

The labeling creates a practical problem. If a patient has obesity without diabetes, insurance will not cover Ozempic (wrong indication) but may cover Zepbound. If a patient has diabetes without obesity, insurance will not cover Zepbound but may cover Ozempic or Mounjaro.

Clinicians prescribe off-label regularly (Ozempic for weight loss, Zepbound for diabetes), but insurance coverage follows FDA labeling. This is the primary reason patients turn to compounded versions, which are not restricted by brand-name labeling.

Cost comparison: brand vs compounded options

Brand-name pricing (without insurance, 2026):

• Ozempic: $950-$1,050 per month
• Zepbound: $1,050-$1,150 per month

With insurance coverage, copays range from $25 to $500+ per month depending on plan formulary.

Compounded pricing (2026 typical range):

• Compounded semaglutide: $250-$400 per month
• Compounded tirzepatide: $450-$600 per month

Compounded tirzepatide costs more than compounded semaglutide because the raw peptide is more expensive to synthesize (dual receptor binding requires more complex chemistry). The price difference mirrors the brand-name difference.

For patients paying out of pocket, compounded semaglutide offers the lowest cost. For patients prioritizing maximum weight loss, compounded tirzepatide offers better efficacy at moderate cost increase.

Insurance rarely covers compounded versions. Patients using compounded medications are almost always self-pay.

What most articles get wrong about GIP receptor activation

Most comparison articles describe GIP as "another incretin hormone" and leave it at that. This misses the mechanism that explains why tirzepatide outperforms semaglutide.

The common error: GIP and GLP-1 both increase insulin secretion, so tirzepatide just has "more incretin effect."

Why that's wrong: GIP receptor activation does increase insulin secretion, but the weight loss advantage comes from GIP's effects on adipose tissue and energy expenditure, not insulin.

The evidence:

• GIP receptor knockout mice are resistant to diet-induced obesity (Miyawaki et al., Nature Medicine, 2002)
• GIP reduces inflammation in adipose tissue and improves adipocyte insulin sensitivity (Samms et al., Science Translational Medicine, 2021)
• GIP receptor agonism increases energy expenditure independent of food intake (Coskun et al., Science Translational Medicine, 2018)

The dual-agonist effect is not additive (GLP-1 effect + GIP effect). It's synergistic. GLP-1 reduces food intake. GIP improves how the body handles stored fat and increases metabolic rate. The combination produces weight loss greater than either alone.

This is why early GIP receptor antagonists (blockers) failed in obesity trials. Blocking GIP seemed logical because GIP increases after meals and promotes fat storage. But chronic GIP agonism (activation) produces the opposite effect: improved fat metabolism and weight loss.

The mechanism is still being worked out, but the clinical result is clear: dual agonism beats single agonism for weight loss.

The FormBlends clinical pattern: who switches and why

Across patient journeys on both compounded semaglutide and compounded tirzepatide, we see consistent switching patterns.

Semaglutide to tirzepatide (most common switch): The typical patient has been on semaglutide for 4-6 months, lost 8-12% of starting weight, and hit a plateau. Weight loss stalls despite being at maximum dose (2.4 mg or equivalent compounded dose). The patient tolerates semaglutide well but wants more weight loss.

Switching to tirzepatide produces an additional 5-8% weight loss over the next 4-6 months in most cases. The patient restarts titration at 2.5 mg tirzepatide (not 5 mg or higher, even though they tolerated high-dose semaglutide). Side effects during the switch are usually mild because the patient has already adapted to GLP-1 effects.

Tirzepatide to semaglutide (less common, specific reasons): The typical patient has severe nausea or vomiting on tirzepatide that doesn't resolve after 8+ weeks. Switching to semaglutide reduces nausea frequency in about 60% of these patients. The tradeoff is accepting slower weight loss.

Another pattern: cost-driven switches. A patient starts on tirzepatide, loses 15-20% of body weight, and switches to semaglutide for maintenance at lower monthly cost. This works if the patient has reached goal weight and needs only weight maintenance, not continued loss.

The pattern we don't see: patients switching back and forth multiple times. Once a patient finds a medication that works and is tolerable, they stay on it. The switching decision is usually one-time and directional.

When Ozempic works better than Zepbound (the steelman case)

The weight loss data favors Zepbound, but there are legitimate clinical scenarios where Ozempic (semaglutide) is the better choice.

Scenario 1: The patient has moderate weight loss goals (10-15% total body weight). If a patient weighs 200 pounds and wants to reach 175 pounds (12.5% loss), semaglutide will get them there at lower cost and with a shorter titration period. Tirzepatide's advantage is overkill for moderate goals.

Scenario 2: The patient has severe nausea sensitivity. Semaglutide causes more nausea than tirzepatide on average, but the nausea is more predictable and dose-dependent. A patient who cannot tolerate tirzepatide 5 mg due to nausea may tolerate semaglutide 0.5 mg and achieve meaningful weight loss at that lower dose. The dose flexibility is better with semaglutide.

Scenario 3: The patient has type 2 diabetes and needs proven cardiovascular benefit. Semaglutide has published cardiovascular outcomes trial data (SUSTAIN-6, Marso et al., New England Journal of Medicine, 2016) showing reduced risk of major adverse cardiovascular events. Tirzepatide does not yet have completed cardiovascular outcomes trials (SURPASS-CVOT is ongoing, results expected 2027). For a patient with established cardiovascular disease, semaglutide's proven CV benefit may outweigh tirzepatide's weight loss advantage.

Scenario 4: The patient prioritizes injection volume. Semaglutide pens deliver 0.25-0.375 mL per injection. Tirzepatide pens deliver 0.5 mL. For patients with injection anxiety or site reactions, smaller volume matters.

Scenario 5: The patient is already on semaglutide and doing well. If a patient has lost 12-15% on semaglutide and is satisfied, there's no reason to switch. The incremental benefit of tirzepatide may not justify restarting titration and risking new side effects.

The steelman case is not that semaglutide is better on average. It's that for specific patients with specific goals and constraints, semaglutide is the rational choice.

The decision framework: which medication for which patient

Choose tirzepatide (Zepbound or compounded) if:

• Weight loss goal is aggressive (≥15% total body weight)
• Patient has already tried semaglutide and plateaued
• Patient tolerates GI side effects well
• Cost difference between semaglutide and tirzepatide is acceptable
• Patient is willing to commit to longer titration schedule

Choose semaglutide (Ozempic, Wegovy, or compounded) if:

• Weight loss goal is moderate (10-15% total body weight)
• Patient has severe nausea sensitivity
• Patient has established cardiovascular disease and needs proven CV benefit
• Cost is the primary constraint
• Patient wants faster time to therapeutic dose

The tiebreaker questions:

1. Has the patient tried either medication before? Start with the one they haven't tried.
2. Does the patient have diabetes? If yes and insurance covers Ozempic, start there. If insurance doesn't cover, compounded tirzepatide may offer better diabetes control.
3. Does the patient have a history of gallbladder disease? Both medications carry similar risk; neither is preferred.
4. Does the patient have a history of pancreatitis? Both medications carry similar risk; consider non-GLP-1 options.
5. Is the patient planning pregnancy within 2 years? Neither medication is appropriate; both require 2-month washout before conception.

Decision tree:

• If weight loss goal >15% AND cost acceptable → tirzepatide
• If weight loss goal 10-15% AND cost is primary concern → semaglutide
• If tried semaglutide and plateaued → switch to tirzepatide
• If severe nausea on tirzepatide → switch to semaglutide
• If diabetes + CV disease → semaglutide (proven CV outcomes)
• If diabetes without CV disease → tirzepatide (better A1c reduction)

Compounded versions: tirzepatide vs semaglutide

Compounded semaglutide and compounded tirzepatide are not FDA-approved and are not interchangeable with brand-name products. They are prepared by state-licensed compounding pharmacies in response to individual prescriptions.

Quality considerations: Both peptides are available from bulk peptide suppliers. Quality varies. Reputable compounding pharmacies source from suppliers that provide certificates of analysis showing >98% purity. Lower-quality suppliers may provide peptides with 90-95% purity, which increases the risk of impurities and inconsistent dosing.

FormBlends works exclusively with compounding pharmacies that source tirzepatide and semaglutide from FDA-registered facilities and provide third-party testing documentation.

Formulation differences:

• Compounded semaglutide: typically formulated with bacteriostatic water or saline, sometimes with B12 added
• Compounded tirzepatide: typically formulated with bacteriostatic water, sometimes with B12 or other additives

The additives (B12, glycine, mannitol) do not change the core mechanism of the peptide. They may affect injection site comfort or stability.

Dosing equivalence: Compounded doses are typically equivalent to brand-name doses on a milligram basis. 1 mg of compounded semaglutide should produce similar effects to 1 mg of brand-name semaglutide, assuming equivalent purity.

The practical difference is in consistency. Brand-name products undergo rigorous batch testing. Compounded products are tested by the compounding pharmacy but not subject to the same FDA oversight. This introduces variability.

Switching between brand and compounded: A patient switching from brand-name Ozempic 1.0 mg to compounded semaglutide 1.0 mg should expect similar effects. A patient switching from brand-name Zepbound 10 mg to compounded tirzepatide 10 mg should expect similar effects.

The reverse (compounded to brand) works the same way. Dose equivalence is milligram-to-milligram.

Availability during shortages: As of April 2026, both semaglutide and tirzepatide remain on the FDA drug shortage list. This allows compounding pharmacies to prepare these medications legally. If the shortage resolves, compounding may become restricted under FDA guidance.

FAQ

Are Zepbound and Ozempic the same drug? No. Zepbound contains tirzepatide, a dual GIP/GLP-1 receptor agonist. Ozempic contains semaglutide, a GLP-1-only receptor agonist. They are different molecules with different mechanisms and different efficacy profiles.

Which is better for weight loss, Zepbound or Ozempic? Zepbound produces greater weight loss. Clinical trials show 20.9% average weight loss for tirzepatide 15 mg vs 14.9% for semaglutide 2.4 mg at 72 weeks. Zepbound is 40% more effective for weight loss on average.

Which has fewer side effects, Zepbound or Ozempic? Ozempic causes more nausea and vomiting (44% vs 33%). Zepbound causes slightly more diarrhea (23% vs 20%). Overall discontinuation rates due to side effects are similar (6-7% for both). Neither has a clear tolerability advantage.

Can I switch from Ozempic to Zepbound? Yes, under provider supervision. The switch requires restarting titration at the lowest Zepbound dose (2.5 mg) even if you were on high-dose Ozempic. The medications are not interchangeable, and your body needs time to adapt to the dual-agonist mechanism.

Can I take Ozempic and Zepbound together? No. Taking both medications together provides no additional benefit and increases side effect risk. The mechanisms overlap (both activate GLP-1 receptors), so combining them is redundant and potentially harmful.

Is compounded tirzepatide the same as Zepbound? Compounded tirzepatide contains the same active ingredient as Zepbound but is not FDA-approved and is not manufactured by Eli Lilly. Quality, purity, and consistency may vary between compounding pharmacies. Compounded tirzepatide is not interchangeable with brand-name Zepbound.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient as Ozempic but is not FDA-approved and is not manufactured by Novo Nordisk. Quality, purity, and consistency may vary. Compounded semaglutide is not interchangeable with brand-name Ozempic or Wegovy.

Does Zepbound work faster than Ozempic? No. Ozempic reaches therapeutic dose faster (week 9-13) compared to Zepbound (week 17-21). However, Zepbound produces greater total weight loss by the end of treatment. Ozempic is faster to therapeutic dose; Zepbound is more effective long-term.

Which costs less, Ozempic or Zepbound? Brand-name Ozempic costs $950-$1,050 per month. Brand-name Zepbound costs $1,050-$1,150 per month. Compounded semaglutide costs $250-$400 per month. Compounded tirzepatide costs $450-$600 per month. Semaglutide options cost less in both brand and compounded forms.

Can I use Ozempic if I don't have diabetes? Ozempic is FDA-approved only for type 2 diabetes. Wegovy (same molecule, different brand) is FDA-approved for obesity. Insurance typically will not cover Ozempic for weight loss alone. Clinicians may prescribe Ozempic off-label for obesity, but coverage is unlikely.

Can I use Zepbound if I have diabetes? Zepbound is FDA-approved only for obesity. Mounjaro (same molecule, different brand) is FDA-approved for type 2 diabetes. Insurance typically will not cover Zepbound for diabetes alone. Clinicians may prescribe Zepbound off-label for diabetes, but coverage is unlikely.

How long does it take to see results with Zepbound vs Ozempic? Most patients see initial weight loss within 4-6 weeks on either medication. Maximum weight loss occurs at 60-72 weeks. Ozempic produces 10-15% total weight loss by week 68. Zepbound produces 15-21% total weight loss by week 72. Both require 12-18 months for full effect.

Do Zepbound and Ozempic have the same thyroid cancer warning? Yes. Both carry a black-box warning about thyroid C-cell tumors based on rodent studies. No human cases have been definitively linked to either medication. Patients with personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2 should not use either medication.

Which medication is better for someone with a history of nausea? Zepbound causes less nausea than Ozempic on average (33% vs 44%). If nausea is a primary concern, starting with Zepbound at the lowest dose (2.5 mg) and titrating slowly may be better tolerated than starting Ozempic.

Can I drink alcohol on Zepbound or Ozempic? Both medications are compatible with moderate alcohol consumption. Alcohol does not interact with the medication directly but may worsen nausea and increase the risk of hypoglycemia in patients taking diabetes medications. Limit alcohol to 1-2 drinks per occasion.

Sources

1. Frias JP et al. Tirzepatide versus semaglutide once weekly in patients with type 2 diabetes. New England Journal of Medicine. 2021.
2. Garvey WT et al. Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2): a double-blind, randomised, multicentre, placebo-controlled, phase 3 trial. Nature Medicine. 2023.
3. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
4. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
5. Miyawaki K et al. Glucose intolerance caused by a defect in the entero-insular axis: a study in gastric inhibitory polypeptide receptor knockout mice. Nature Medicine. 2002.
6. Samms RJ et al. GIPR agonism mediates weight-independent insulin sensitization by tirzepatide in obese mice. Science Translational Medicine. 2021.
7. Coskun T et al. LY3298176, a novel dual GIP and GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus: From discovery to clinical proof of concept. Science Translational Medicine. 2018.
8. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
9. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
10. Rosenstock J et al. Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1): a double-blind, randomised, phase 3 trial. Lancet. 2021.
11. Dahl D et al. Effect of subcutaneous tirzepatide vs placebo added to titrated insulin glargine on glycemic control in patients with type 2 diabetes: the SURPASS-5 randomized clinical trial. JAMA. 2022.
12. Aroda VR et al. Comparative efficacy, safety, and cardiovascular outcomes with once-weekly subcutaneous semaglutide in the treatment of type 2 diabetes: Insights from the SUSTAIN 1-7 trials. Diabetes & Metabolism. 2019.
13. Blonde L et al. Interpretation and impact of real-world clinical data for the practicing clinician: focus on glucagon-like peptide-1 receptor agonists for type 2 diabetes. Diabetes Therapy. 2019.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2026. Diabetes Care. 2026.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Zepbound and Mounjaro are registered trademarks of Eli Lilly and Company. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. FormBlends is not affiliated with, endorsed by, or sponsored by Eli Lilly and Company or Novo Nordisk.